FDA approves new drug to treat Alzheimer's disease

FDA approves new drug to treat Alzheimer's disease

Publication date: Jun 08, 2021

The drug reportedly is not for people with severe Alzeheimer’s but may be used to help offset early onset Alzeheimer’s symtoms. . Biogen’s medication is called Aducanumab and it’s for mild cognitive impairment associated with the early stages of the brain wasting disease. It will take several months for the drug to become available for most patients. Critics have expressed concerns that the drug may be too expensive. Some non-profits didn’t think the medication should be approved, though, the Alzheimer’s Association supported it. -It’s very exciting to get the FDA’s provisional approval today this is a major moment in history. We spoke with Dr. Jonathan Liss at the Columbus Memory Center about the historic day.

Concepts Keywords
Alzheimer Health
Alzheimers Monoclonal antibodies
Biogens Medicine
Columbus Branches of biology
Diseasecolumbus Mild cognitive impairment
Drugs Alzheimer’s disease
Fda Aducanumab
Drug
WTVM
Gray Television
Psychiatric diagnosis
Cognitive disorders

Semantics

Type Source Name
drug DRUGBANK Aducanumab
disease MESH mild cognitive impairment
disease MESH wasting disease
drug DRUGBANK Nonoxynol-9

Original Article

Leave a Comment

Your email address will not be published. Required fields are marked *